Ligand Pharma Elects Board Members at Annual Meeting

Ligand Pharma ( (LGND) ) has provided an update.

On June 6, 2025, Ligand Pharmaceuticals held its Annual Meeting of Stockholders where eight board members were elected for terms expiring in 2026. Additionally, the selection of Ernst & Young LLP as the company’s independent registered public accounting firm for 2025 was ratified, and a non-binding advisory resolution on executive compensation was approved.

The most recent analyst rating on (LGND) stock is a Buy with a $130.00 price target. To see the full list of analyst forecasts on Ligand Pharma stock, see the LGND Stock Forecast page.

Spark’s Take on LGND Stock

According to Spark, TipRanks’ AI Analyst, LGND is a Neutral.

Ligand Pharmaceuticals receives a moderate score driven by strong earnings call results and strategic corporate events, which are offset by weak financial performance and valuation metrics. Despite challenges with declining revenues and profitability, the company’s strategic investments and product launches provide a positive outlook.

To see Spark’s full report on LGND stock, click here.

More about Ligand Pharma

Ligand Pharmaceuticals is a company operating in the pharmaceutical industry, focusing on the development and acquisition of technologies that aid in drug discovery and development.

Average Trading Volume: 120,408

Technical Sentiment Signal: Buy

Current Market Cap: $2.04B

For a thorough assessment of LGND stock, go to TipRanks’ Stock Analysis page.